|
Corinne Hoff |
Satoshi Sugimoto |
|
Global Media Relations |
Global Media Relations |
|
Novartis International AG |
Novartis International AG |
Assemblée générale ordinaire du 6 mars 2007
| Source: Novartis Pharma AG
Recommended Reading
-
If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹Recommendation based...
Read More -
Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options ...
Read More